Polaryx Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Polaryx Therapeutics reported a net loss of $1.4 million for Q2 2026, with operating expenses increasing, though cash reserves grew due to financing activities, providing an estimated runway through Q1 2027.